Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: A method may include: oxidizing iso-butane with oxygen to produce t-butyl hydroperoxide and t-butyl alcohol; dehydrating at least a portion of the t-butyl alcohol to produce di-tert-butyl ether and isobutylene; epoxidizing at least a portion of the isobutylene with the t-butyl hydroperoxide to produce isobutylene oxide and t-butyl alcohol; and carbonylating at least a portion of the isobutylene oxide with carbon monoxide to produce pivalolactone.

Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.

Abstract: Pharmaceutical compounds are disclosed which may be useful for treating asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and/or emphysema. A pharmaceutical composition may include a therapeutically effective amount of the compound and a pharmaceutically acceptable vehicle therefor. The pharmaceutical composition may be administered for treating such disorders as asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema.

Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

Abstract: The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

Abstract: The invention relates to a method for producing aniline or an aniline derivative, in which a solution of aminobenzoic acid in aniline with a mass fraction of aniline in the solution, in relation to the total mass of aminobenzoic acid and aniline, in the region of 20% to 85%, is subject to a thermal decarboxylation at a temperature in the region of 165° C. to 500° C. without the presence of a non-system catalyst, such that the aminobenzoic acid is converted into aniline. The obtained aniline can be converted into derivatives, such as di- and polyamines of the diphenylmethane series.

Abstract: A process for the production of furfural from a biphasic composition including furfural, an organic solvent and soluble organic debris. The said process includes subjecting the biphasic composition to a liquid-liquid separation step to provide an organic phase and an aqueous phase. The organic phase includes the organic solvent, a first portion of the furfural and a first portion of soluble organic debris. The aqueous phase includes a remainder portion of the furfural and a remainder portion of soluble organic debris. The organic phase is subjected to a distillation step to provide a furfural stream and an organic solvent stream including the organic solvent and the first portion of the soluble organic debris. The organic solvent stream is conveyed to an adsorption unit to adsorb a second portion of the soluble organic debris, forming an organic debris-depleted recycle stream.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: A process for the continuous production of a reaction product of a diazo-compound and a substrate in a multi-stage flow reactor is disclosed.

Abstract: The present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug, wherein the method comprises administering to a subject a compound having the structure of formula (I): having the IUPAC name of (?)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol, or pharmaceutically acceptable esters or salts thereof, wherein the compound has activity on the mu, delta and kappa opioid receptors thereby providing added analgesia with an improved therapeutic index and reduced risk of respiratory depression.

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Abstract: The present invention relates in part protective groups that can be used to reversibly protect benzoxaboroles and yield the corresponding protected complexes. The invention further relates to the use of these protective groups to protect benzoxaboroles.

Abstract: This application discloses a method for synthesizing myricetin, which includes the following steps: adding an alkaline solution to an aqueous solution of dihydromyricetin, and heating under a reflux state after the addition; adding an aqueous solution of selenium dioxide, stirring at a reflux temperature after the addition, and cooling to room temperature after the reaction is complete; adding acid to adjust pH, stirring, rotary evaporation, stirring, and filtering; adding an aqueous solution of ethanol to a filter cake to make a slurry, filtering, washing the filter cake with the aqueous solution of ethanol, collecting the filter cake and drying to obtain red selenium; combining organic phases, spin-drying until there is no ethanol smell, precipitating a large amount of solids, filtering, and washing the filter cake with the aqueous solution of ethanol to obtain a yellow solid which is myricetin. The advantages of the disclosure are: 1. simple and easy to operate the reaction; 2.

Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.